Organon

OGN · NYSE · United States

Share price · OGN

$13.92+0.24 (+1.75%) 3M

close as of 2026-11-18 · 24h delayed · vol 3.9M (1.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when OGN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 27 Apr 2026+16.9%
  2. 24 Apr 2026+30.9%
  3. 10 Apr 2026+27.8%
  4. 9 Apr 2026+17.9%
  5. 25 Feb 2026-7.7%
  6. 20 Feb 2026+7.7%
  7. 12 Feb 2026-8.2%
  8. 26 Jan 2026-6.8%

    Nothing announced by OGN that day or the session before.

Share of unusual movement by asset

For each asset, the share of OGN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Tapinarof
events and moves
82%
Ezetimibe (Zetia)
events and moves
1shown from 8 days
adalimumab-bwwd (Hadlima) (Hadlima)
events and moves
1shown from 8 days
BAT1806 (Tofidence)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—35%
Sessions with no dated event—63%

Assets

(12 total)
12Total Assets
11Approved
0Phase 3 / Filed
1Phase 1–2 / Early
15Diseases
Quick filter:
Showing 12 of 12 assets
Target & Modality
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis
Ulcerative Colitis, Crohn's Disease
Approved
Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule
SchizophreniaBipolar Disorder
BAT1806(Tofidence)
Approved
IL-6 receptorMonoclonal antibody
Rheumatoid ArthritisCOVID-19
Ezetimibe(Zetia)
Approved
Dietary Cholesterol Absorption Inhibitor · NPC1L1Small molecule
Atherosclerotic Cardiovascular DiseaseHomozygous Familial HypercholesterolemiaMixed Hyperlipidemia
Approved
HMG-CoA reductase / NPC1L1Small molecule
Atherosclerotic Cardiovascular DiseaseHomozygous Familial Hypercholesterolemia
Approved
TNF-alphaMonoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid Arthritis
Ulcerative Colitis, Crohn's Disease
Approved
Glucocorticoid receptor; Beta-2 adrenergic receptorSmall molecule
Asthma
Approved
Cysteinyl leukotriene receptor 1 (CysLT1)Small molecule
Asthma
Approved
5-HT1B/1D receptorSmall molecule
Migraine
Approved
Aryl hydrocarbon receptor · Aryl Hydrocarbon Receptor AgonistSmall molecule
Atopic DermatitisPsoriasis
Approved
IL-12 p40Monoclonal antibody
Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis
Ulcerative Colitis, Crohn's Disease
Preclinical / Unstaged
HMG-CoA reductase / NPC1L1Small molecule
Atherosclerotic Cardiovascular Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
August 2027 (1)
TapinarofPhase 3Atopic Dermatitis
Est. primary completion 2027-08 · NCT07265479 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 November 2024Topline resultEzetimibeTANDEM Phase 3 topline: obicetrapib/ezetimibe fixed-dose combination

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$1.6B$83M$1.5B—$370M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.6B$90M$1.1B—$107M operating cash flowreport ↗
2026-Q1$1.5B$93M$1.1B—$225M operating cash flowreport ↗
2025-Q3$1.6B$84M$672M—$264M operating cash flowreport ↗
2025-Q2$1.6B$95M$599M—$220M operating cash flowreport ↗
2025-Q1$1.5B$96M$547M—$75M operating cash flowreport ↗
2024-Q3$1.6B$111M$763M—$141M operating cash flowreport ↗
2024-Q2$1.6B$116M$704M—$332M operating cash flowreport ↗
2024-Q1$1.6B$112M$575M—$76M operating cash flowreport ↗
2023-Q3$1.5B$137M$414M—$261M operating cash flowreport ↗
2023-Q2$1.6B$128M$326M—$27M operating cash flowreport ↗
2023-Q1$1.5B$129M$459M—$114M operating cash flowreport ↗
2022-Q3$1.5B$127M$499M—$317M operating cash flowreport ↗
2022-Q2$1.6B$106M$545M—$151M operating cash flowreport ↗
2022-Q1$1.6B$96M$694M—$123M operating cash flowreport ↗
2021-Q3$1.6B$86M$1.0B—report ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$6.2B$366M$574M—$700M operating cash flowreport ↗

Organon reported full-year 2025 revenue of $6,216M, down 2.9% YoY, with R&D spend of $366M (down 22.0% YoY) and cash and equivalents of $574M. Net income was $187M for the year, and the company posted a fourth-quarter net loss of $205M, including a $301M non-cash goodwill impairment. Diluted EPS for the full year was $0.72.

For 2026, Organon expects revenue of approximately $6.2B and Adjusted EBITDA of approximately $1.9B, both roughly in line with 2025. The company highlighted FDA approvals of biosimilars Bildyos and Bilprevda in the third quarter of 2025, the acquisition of Tofidence in the second quarter of 2025, and the completed divestiture of the JADA system in January 2026. It also disclosed that its Audit Committee will review the timing of prior-year biosimilar purchases from a supplier, with no determination yet that anything inappropriate occurred.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$6.4B$469M$675M—$939M operating cash flowreport ↗
2023-FY$6.3B$528M$693M—$799M operating cash flowreport ↗
2022-FY$6.2B$471M$706M—$858M operating cash flowreport ↗
2021-FY$6.3B$339M$737M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($353K), 2 sales ($553K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13Morrissey Joseph T. Jr. · CEOOption exercise43,744——Form 4
2026-11-13Drinane Juliana Papa · Head of Mfg & SupplyOption exercise21,872——Form 4
2026-11-13Morrissey Joseph T. Jr. · CEOTax withholding13,551$13.90$188KForm 4
2026-11-13Drinane Juliana Papa · Head of Mfg & SupplyTax withholding7,492$13.90$104KForm 4
2026-11-13Morrissey Joseph T. Jr. · CEOOption exercise (derivative)43,744——Form 4
2026-11-13Drinane Juliana Papa · Head of Mfg & SupplyOption exercise (derivative)21,872——Form 4
2026-11-07Arjona Ferreira Juan Camilo · Head of R&D & CMOOption exercise6,447——Form 4
2026-11-07Drinane Juliana Papa · Head of Mfg & SupplyOption exercise3,626——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 601 reporting institutions held 199.2M shares ($1.1B).

#InstitutionSharesValue
1BlackRock, Inc.31,717,028$190.0M
2VANGUARD PORTFOLIO MANAGEMENT LLC21,846,036$130.9M
3VANGUARD CAPITAL MANAGEMENT LLC11,737,018$70.3M
4STATE STREET CORP9,956,774$59.6M
5MILLENNIUM MANAGEMENT LLC6,781,535$40.6M
6KAHN BROTHERS GROUP INC5,536,993$33.2M
7CANADA PENSION PLAN INVESTMENT BOARD5,011,100$30.0M
8GEODE CAPITAL MANAGEMENT, LLC4,759,337$28.5M
9PRIVATE MANAGEMENT GROUP INC4,374,108$26.2M
10Think Investments LP4,000,000$24.0M
11UBS Group AG3,471,579$20.8M
12AQR CAPITAL MANAGEMENT LLC3,450,626$20.2M
13CHARLES SCHWAB INVESTMENT MANAGEMENT INC3,362,349$20.1M
14MORGAN STANLEY3,292,684$19.7M
15DIMENSIONAL FUND ADVISORS LP3,265,280$19.6M